3 January 2024 Aktis Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference read more
3 January 2024 ReCode Therapeutics Doses First Patient in Phase 1 Clinical Study of Novel mRNA-based Therapy for the Treatment of Primary Ciliary Dyskinesia read more
13 December 2023 Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Myasthenia Gravis read more
28 November 2023 Tectonic Therapeutic Announces Start of First Clinical Program for GPCR-Targeted Biologic read more
17 November 2023 Kyverna Therapeutics Announces Publication in The Lancet Neurology of Case Report of Patient with Refractory Myasthenia Gravis Treated with Investigational KYV-101 read more
